- Home
- SNDX vs MDXG Comparison
SNDX vs MDXG Comparison
Compare SNDX & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- MDXG
- Stock Information
- Founded
- SNDX 2005
- MDXG 2006
- Country
- SNDX United States
- MDXG United States
- Employees
- SNDX N/A
- MDXG N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- MDXG Biotechnology: Pharmaceutical Preparations
- Sector
- SNDX Health Care
- MDXG Health Care
- Exchange
- SNDX Nasdaq
- MDXG Nasdaq
- Market Cap
- SNDX 1.1B
- MDXG 1.1B
- IPO Year
- SNDX 2016
- MDXG N/A
- Fundamental
- Price
- SNDX $16.24
- MDXG $7.31
- Analyst Decision
- SNDX Strong Buy
- MDXG Buy
- Analyst Count
- SNDX 10
- MDXG 1
- Target Price
- SNDX $37.50
- MDXG $12.00
- AVG Volume (30 Days)
- SNDX 2.9M
- MDXG 775.7K
- Earning Date
- SNDX 08-04-2025
- MDXG 07-30-2025
- Dividend Yield
- SNDX N/A
- MDXG N/A
- EPS Growth
- SNDX N/A
- MDXG N/A
- EPS
- SNDX N/A
- MDXG 0.21
- Revenue
- SNDX $77,933,000.00
- MDXG $363,774,000.00
- Revenue This Year
- SNDX $434.67
- MDXG $9.55
- Revenue Next Year
- SNDX $108.62
- MDXG $11.43
- P/E Ratio
- SNDX N/A
- MDXG $34.25
- Revenue Growth
- SNDX 2126.66
- MDXG 6.85
- 52 Week Low
- SNDX $8.58
- MDXG $5.47
- 52 Week High
- SNDX $22.50
- MDXG $10.14
- Technical
- Relative Strength Index (RSI)
- SNDX 79.83
- MDXG 59.42
- Support Level
- SNDX $15.36
- MDXG $7.01
- Resistance Level
- SNDX $16.33
- MDXG $7.27
- Average True Range (ATR)
- SNDX 0.78
- MDXG 0.22
- MACD
- SNDX 0.31
- MDXG -0.01
- Stochastic Oscillator
- SNDX 96.87
- MDXG 75.00
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.